Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

ReShape Lifesciences stock

RSLS
US7611236032

Price

5.24
Today +/-
+0.07
Today %
+1.34 %
P

ReShape Lifesciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ReShape Lifesciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ReShape Lifesciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ReShape Lifesciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ReShape Lifesciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ReShape Lifesciences Stock Price History

DateReShape Lifesciences Price
11/15/20245.24 undefined
11/14/20245.17 undefined
11/13/20245.69 undefined
11/12/20245.36 undefined
11/11/20245.66 undefined
11/8/20245.60 undefined
11/7/20245.38 undefined
11/6/20245.89 undefined
11/5/20246.02 undefined
11/4/20246.05 undefined
11/1/20245.88 undefined
10/31/20245.65 undefined
10/30/20245.45 undefined
10/29/20245.93 undefined
10/28/20245.74 undefined
10/25/20245.48 undefined
10/24/20245.67 undefined
10/23/20245.90 undefined
10/22/20245.95 undefined
10/21/20246.62 undefined

ReShape Lifesciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ReShape Lifesciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ReShape Lifesciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ReShape Lifesciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ReShape Lifesciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ReShape Lifesciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ReShape Lifesciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ReShape Lifesciences’s growth potential.

ReShape Lifesciences Revenue, EBIT and net profit per share

DateReShape Lifesciences RevenueReShape Lifesciences EBITReShape Lifesciences Net Income
2026e25.74 M undefined-30.46 M undefined-482,178.6 undefined
2025e12.23 M undefined-5.93 M undefined-187,272 undefined
2024e10.19 M undefined-6.84 M undefined-234,089.99 undefined
20238.68 M undefined-14.64 M undefined-11.39 M undefined
202211.24 M undefined-27.08 M undefined-46.21 M undefined
202113.6 M undefined-27.23 M undefined-63.15 M undefined
20201.59 M undefined-10.64 M undefined-12.33 M undefined
20193.28 M undefined-23.23 M undefined-23.68 M undefined
20189.1 M undefined-36.97 M undefined-37.38 M undefined
20179.91 M undefined-34.39 M undefined-34.77 M undefined
20163.39 M undefined-19.51 M undefined-20.47 M undefined
20154.04 M undefined-14.93 M undefined-15.56 M undefined
20143.54 M undefined-9.84 M undefined-9.89 M undefined
20130 undefined-24.73 M undefined-25.78 M undefined
2012310,000 undefined-22.55 M undefined-23.46 M undefined
20110 undefined-25.26 M undefined-26 M undefined
20100 undefined-16.18 M undefined-17.35 M undefined
20090 undefined-24.21 M undefined-31.93 M undefined
20080 undefined-36.27 M undefined-37.88 M undefined
20070 undefined-28.03 M undefined-28.58 M undefined
20060 undefined-18.12 M undefined-17.69 M undefined
20050 undefined-11.15 M undefined-11.22 M undefined
20040 undefined-3.25 M undefined-3.45 M undefined

ReShape Lifesciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0000000000343993113118101225
-----------33.33-25.00200.00--66.67-66.671,200.00-15.38-27.2725.0020.00108.33
----------166.6725.00166.6755.5633.33166.67500.0061.5454.5562.5050.0041.6720.00
00000000000105300865000
-3-11-17-28-37-31-17-26-23-25-9-15-20-34-37-23-12-63-46-11000
-266.6754.5564.7132.14-16.22-45.1652.94-11.548.70-64.0066.6733.3370.008.82-37.84-47.83425.00-26.98-76.09---
00000000001010101010300220420102.69000
-----------------------
Details

Keystats

ⓘ

Revenue and Growth

The ReShape Lifesciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ReShape Lifesciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
10.7234.7357.0326.314.6230.8429.4922.3123.319.2412.5375.4844.423.7414.063.9122.773.864.46
00000000.050.020.250.640.524.220.870.2902.822.181.66
0000000000.060.0200.090.0103.15000
0000001.071.271.130.450.360.831.421.581.94033.613.74
0.140.070.430.420.476.9710.770.550.230.241.241.632.451.960.781.360.260.44
10.8634.857.4626.7215.0937.8131.5624.42520.2313.7978.0751.7628.6518.257.8429.959.9110.3
0.641.11.491.260.970.740.630.610.580.480.420.721.351.742.161.481.720.870.31
0000000000000000000
0000000000000000000
000000000000000020.830.260
0000000000000000000
0.040.010.010.220.150.140.291.080.820000001.30.050.10.06
0.681.111.51.481.120.880.921.691.40.480.420.721.351.742.162.7822.61.230.37
11.5435.9158.9628.216.2138.6932.4826.0926.420.7114.2178.7953.1130.3920.4110.6252.5511.1410.66
                                     
0.060.110.170.170.370.280.370.420.6454.8354.70.020.020.020.010.01000.02
19.1863.39108.59112.55138.58180.14196.39211.632400.731140.9146.47161.84188.27189.42622.4627.94642.3
-17.17-34.86-63.43-101.31-133.37-150.71-176.71-200.17-225.95-40.59-56.14-76.61-111.37-148.75-172.43-184.76-577.97-624.19-635.57
-0.09-0.07-0.04-0.0100000-0.0100-0.01000-0.09-0.09-0.09
0000000000000000000
1.9828.5745.2911.45.5829.7120.0511.8814.6914.96-0.4464.3135.1113.1115.854.6744.343.666.66
0.320.680.30.160.030.130.430.340.130.180.550.61.281.160.650.623.471.931.69
0.931.72.373.042.372.956.824.24.710.642.6646.275.792.884.432.594.091.17
0000000000.061.6200.510.350.4201.481.460.92
0000000000000000000
12.655.082.683.880.922.313400.7501.969.930.020000
2.255.037.755.886.2849.567.548.840.885.584.610.0217.233.975.057.547.483.78
7.341.736.02113.884.982.886.682.874.889.099.887.96000.43000
000000000000000037000
073000470000000010505704803000223
7.342.466.02114.354.982.886.682.874.889.099.887.970.050.570.910.6700.22
9.597.4913.7716.8810.638.9812.4414.2211.715.7614.6714.4817.9917.284.545.968.217.484
11.5736.0659.0628.2816.2138.6932.4926.126.420.7214.2378.7953.130.3920.3910.6352.5511.1410.66
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ReShape Lifesciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ReShape Lifesciences's financial health and stability.

Assets

ReShape Lifesciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ReShape Lifesciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ReShape Lifesciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ReShape Lifesciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2004200520062007200820092010201120122013201420152016201720182019202020212022
-3-11-17-28-37-31-17-26-23-25-9-15-20-34-37-23-12-61-46
0000000000000000012
0000000000000000000
00100002-31030-12-3-1-20
000437234600144324721
0000120000000000000
0000000000000000000
-3-10-16-23-33-24-13-19-22-18-9-11-19-30-29-22-10-15-21
0000000000000-1-10000
00-17825-6500-726-21192010
00-17935-6510-726-20202020
0000000000000000000
08173-6-104-315000-100-90
7739400204014112420082010230463
8164046313361215192258209130333
----1.00---2.00-1.00--1.00--------3.00-
0000000000000000000
45631-27-616-2-604-369-510-7-1019-18
-3.35-10.73-16.87-24.17-33.91-24.85-13.66-20.19-22.56-18.85-10.18-11.53-19.72-31.66-30.71-23.06-10.58-15.73-22.03
0000000000000000000

ReShape Lifesciences stock margins

The ReShape Lifesciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ReShape Lifesciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ReShape Lifesciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ReShape Lifesciences's sales revenue. A higher gross margin percentage indicates that the ReShape Lifesciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ReShape Lifesciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ReShape Lifesciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ReShape Lifesciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ReShape Lifesciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ReShape Lifesciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ReShape Lifesciences Margin History

ReShape Lifesciences Gross marginReShape Lifesciences Profit marginReShape Lifesciences EBIT marginReShape Lifesciences Profit margin
2026e63.93 %-118.35 %-1.87 %
2025e63.93 %-48.51 %-1.53 %
2024e63.93 %-67.14 %-2.3 %
202363.93 %-168.69 %-131.22 %
202260.5 %-240.93 %-411.12 %
202161.4 %-200.22 %-464.34 %
202036.48 %-669.18 %-775.47 %
201910.06 %-708.23 %-721.95 %
201840.44 %-406.26 %-410.77 %
201751.36 %-347.02 %-350.86 %
201617.11 %-575.52 %-603.83 %
201538.12 %-369.55 %-385.15 %
201417.8 %-277.97 %-279.38 %
201363.93 %0 %0 %
201225.81 %-7,274.19 %-7,567.74 %
201163.93 %0 %0 %
201063.93 %0 %0 %
200963.93 %0 %0 %
200863.93 %0 %0 %
200763.93 %0 %0 %
200663.93 %0 %0 %
200563.93 %0 %0 %
200463.93 %0 %0 %

ReShape Lifesciences Stock Sales Revenue, EBIT, Earnings per Share

The ReShape Lifesciences earnings per share therefore indicates how much revenue ReShape Lifesciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ReShape Lifesciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ReShape Lifesciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ReShape Lifesciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ReShape Lifesciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ReShape Lifesciences Revenue, EBIT and net profit per share

DateReShape Lifesciences Sales per ShareReShape Lifesciences EBIT per shareReShape Lifesciences Earnings per Share
2026e50.47 undefined0 undefined-0.95 undefined
2025e23.99 undefined0 undefined-0.37 undefined
2024e19.99 undefined0 undefined-0.46 undefined
202384.51 undefined-142.56 undefined-110.89 undefined
202226.76 undefined-64.48 undefined-110.02 undefined
202161.82 undefined-123.77 undefined-287.05 undefined
20200 undefined0 undefined0 undefined
2019109.33 undefined-774.33 undefined-789.33 undefined
2018910 undefined-3,697 undefined-3,738 undefined
2017991 undefined-3,439 undefined-3,477 undefined
2016339 undefined-1,951 undefined-2,047 undefined
2015404 undefined-1,493 undefined-1,556 undefined
2014354 undefined-984 undefined-989 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined

ReShape Lifesciences business model

ReShape Lifesciences Inc is a medical company that was founded in 2018 and is headquartered in San Clemente, California. The company is involved in the development and marketing of medical devices for the treatment of obesity and metabolic disorders. The company's business model focuses on innovative medical devices and services for the treatment of obesity and metabolic disorders. The company's main goal is to help patients improve their weight and health in a non-surgical way. The company offers not only medical devices but also services such as physician consulting, training for medical professionals, and patient support. The company's core products include the ReShape Vest, a non-invasive weight loss therapy approach, and the ReShape Duo System, a secondary gastric balloon system used in combination with a dietary program to support weight reduction. The company also offers the ReShape Care Plan, a comprehensive program for patients with obesity that is managed by a multidisciplinary team. The program includes individual sessions with a certified dietitian and a behavioral coach to motivate patients through concrete guidance for weight reduction. ReShape Lifesciences is dedicated to research and development of medical devices and services that help patients in weight reduction and improving their health. The company aims to create an affordable, safe, and effective treatment for obesity patients in an innovative manner that aligns with healthcare reform. ReShape Lifesciences is one of the most popular companies on Eulerpool.com.

ReShape Lifesciences SWOT Analysis

Strengths

ReShape Lifesciences Inc possesses an innovative and unique technology that differentiates it from competitors in the market. This technology provides the company with a competitive advantage, allowing it to deliver effective and efficient solutions to the healthcare industry.

The company holds a strong intellectual property portfolio, which acts as a barrier to entry for potential competitors. This provides ReShape Lifesciences Inc with the ability to protect its technologies and maintain market dominance.

ReShape Lifesciences Inc has built a reputable brand over the years, providing high-quality products and services to its customers. This established brand reputation enhances customer trust and loyalty, contributing to the company's market share and growth.

Weaknesses

ReShape Lifesciences Inc currently has a limited market reach, primarily targeting specific regions or customer segments. This restricts the company's potential for broader revenue streams and higher market penetration. Expanding its market reach could be a strategic opportunity.

The company heavily relies on key suppliers to provide necessary components or materials for its products. Any disruptions in the supply chain can have a significant impact on ReShape Lifesciences Inc's operations and ability to meet customer demands.

Being a healthcare company, ReShape Lifesciences Inc faces regulatory compliance challenges. Adhering to strict regulations and obtaining necessary approvals can be time-consuming and costly, potentially impacting product development timelines or market entry.

Opportunities

With the rising preference for non-invasive medical procedures, ReShape Lifesciences Inc can capitalize on the growing demand for its innovative technologies that offer effective yet non-surgical treatment options. This presents an opportunity for market expansion and revenue growth.

Forming strategic partnerships and collaborations with healthcare providers or medical technology companies can enhance ReShape Lifesciences Inc's market presence and distribution network. Such partnerships can facilitate access to new customers and geographic regions.

The continuous advancements in healthcare technology open doors for ReShape Lifesciences Inc to further enhance its existing product offerings or develop new solutions. Staying at the forefront of technological innovation can help the company maintain its competitive edge.

Threats

The healthcare industry is highly competitive, with numerous companies vying for market share. ReShape Lifesciences Inc faces the threat of intense competition from both established players and new entrants, which can impact its market position and profitability.

During economic downturns or financial crises, healthcare spending may be reduced, affecting the adoption of new medical technologies. Additionally, ReShape Lifesciences Inc may face funding challenges in terms of securing investments or accessing capital for research and development initiatives.

The healthcare industry operates within a constantly evolving regulatory environment. Changes in regulations or policies can create uncertainties for ReShape Lifesciences Inc, requiring the company to adapt its strategies and ensure compliance, which can entail additional costs and complexities.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ReShape Lifesciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ReShape Lifesciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ReShape Lifesciences shares outstanding

The number of shares was ReShape Lifesciences in 2023 — This indicates how many shares 102,690 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ReShape Lifesciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ReShape Lifesciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ReShape Lifesciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ReShape Lifesciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ReShape Lifesciences stock splits

In ReShape Lifesciences's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for ReShape Lifesciences.

ReShape Lifesciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-9.47 -5.22  (44.85 %)2024 Q1
12/31/2023-10.65 -6.4  (39.93 %)2023 Q4
9/30/2023-70.99 -46.4  (34.64 %)2023 Q3
6/30/2023-105.9 -62.64  (40.85 %)2023 Q2
3/31/2023-249.06 -90.48  (63.67 %)2023 Q1
12/31/2022-591.6 -498.22  (15.78 %)2022 Q4
9/30/2022-1,050.09 -1,508  (-43.61 %)2022 Q3
6/30/2022-1,064.88 -1,450  (-36.17 %)2022 Q2
3/31/2022-1,020.51 -1,276  (-25.04 %)2022 Q1
12/31/2021-517.65 -1,566  (-202.52 %)2021 Q4
1
2
3

ReShape Lifesciences shareholders

%
Name
Stocks
Change
Date
7.33471 % Schneid (Yair)37,407-5,0249/23/2024
1.05824 % Creand Wealth Management5,3975,1738/31/2024
1.05824 % BNP Paribas Investment Partners Espa¿a SA SGIIC5,3975,1728/31/2024
0.45255 % Nachtrab (Matthew)2,3082,3082/15/2023
0.44824 % Geode Capital Management, L.L.C.2,2861,9706/30/2024
0.19922 % Virtu Americas LLC1,0161,0166/30/2024
0.19529 % UBS Financial Services, Inc.9969966/30/2024
0.16863 % The Vanguard Group, Inc.86006/30/2024
0.11510 % BlackRock Institutional Trust Company, N.A.58706/30/2024
0.06647 % HRT Financial LP3393396/30/2024
1
2
3
4

ReShape Lifesciences Executives and Management Board

Mr. Thomas Stankovich(63)
ReShape Lifesciences Chief Financial Officer
Compensation 555,838
Mr. Paul Hickey(59)
ReShape Lifesciences President, Chief Executive Officer, Director (since 2022)
Compensation 158,078
Mr. Dan Gladney(70)
ReShape Lifesciences Executive Chairman of the Board (since 2015)
Compensation 95,261
Mr. Gary Blackford(66)
ReShape Lifesciences Lead Independent Director
Compensation 77,000
Ms. Lori Mcdougal(62)
ReShape Lifesciences Independent Director
Compensation 57,500
1
2

Most common questions regarding ReShape Lifesciences

What values and corporate philosophy does ReShape Lifesciences represent?

ReShape Lifesciences Inc represents the values of innovation, patient-centric approach, and commitment to improving the lives of individuals struggling with obesity and metabolic diseases. The company's corporate philosophy revolves around developing and delivering advanced solutions for weight loss and metabolic health management. With a strong focus on research and development, ReShape Lifesciences strives to provide effective and minimally invasive medical devices that offer long-term solutions for patients. By continuously evolving and advancing their technologies, the company aims to empower individuals to achieve sustainable weight loss and lead healthier lives.

In which countries and regions is ReShape Lifesciences primarily present?

ReShape Lifesciences Inc is primarily present in the United States.

What significant milestones has the company ReShape Lifesciences achieved?

ReShape Lifesciences Inc has achieved significant milestones in its growth as a medical device company. Some notable achievements include the development and FDA clearance of the ReShape Duo, a non-surgical weight loss solution. The company has also successfully expanded its commercial footprint and established partnerships with healthcare providers. ReShape Lifesciences Inc has demonstrated its commitment to innovation by securing a number of patents for its products. Additionally, the company has made strategic acquisitions, such as acquiring the Lap-Band gastric banding system, which has further strengthened its position in the weight loss market.

What is the history and background of the company ReShape Lifesciences?

ReShape Lifesciences Inc, formerly known as EnteroMedics Inc, is a medical device company focused on the development and commercialization of innovative technologies to treat obesity and other metabolic diseases. The company's primary product, the ReShape Vest System, is an FDA-approved non-surgical weight loss solution that uses dual balloons to occupy space within the stomach, promoting feelings of fullness and reducing food intake. ReShape Lifesciences Inc was founded in 2002 and is headquartered in San Clemente, California. With a strong commitment to addressing the global obesity epidemic, the company continues to research and develop new medical devices to improve patient outcomes in the field of metabolic health.

Who are the main competitors of ReShape Lifesciences in the market?

The main competitors of ReShape Lifesciences Inc in the market are Medtronic plc, Apollo Endosurgery Inc, and EnteroMedics Inc.

In which industries is ReShape Lifesciences primarily active?

ReShape Lifesciences Inc is primarily active in the medical devices and healthcare industries.

What is the business model of ReShape Lifesciences?

The business model of ReShape Lifesciences Inc is centered around providing innovative medical devices and therapies for weight loss and obesity management. The company focuses on developing and commercializing minimally invasive solutions that can help individuals achieve their weight loss goals effectively and safely. With a strong emphasis on medical technology, ReShape Lifesciences Inc aims to improve the quality of life for patients struggling with obesity through devices like the ReShape Balloon System. Through its advanced products and commitment to patient care, ReShape Lifesciences Inc seeks to address the global health challenge of obesity effectively.

What is the P/E ratio of ReShape Lifesciences 2024?

The ReShape Lifesciences P/E ratio is -2.3.

What is the P/S ratio of ReShape Lifesciences 2024?

The ReShape Lifesciences P/S ratio is 0.05.

What is the Quality Investing of ReShape Lifesciences?

The Quality Investing for ReShape Lifesciences is 4/10.

What is the revenue of ReShape Lifesciences 2024?

The expected ReShape Lifesciences revenue is 10.19 M USD.

How high is the profit of ReShape Lifesciences 2024?

The expected ReShape Lifesciences profit is -234,089.99 USD.

What is the business model of ReShape Lifesciences

ReShape Lifesciences Inc is a leading company in the field of medical innovations and follows a business model based on the development, manufacturing, and marketing of medical devices and technologies. The company operates in various areas, including the treatment of obesity, gastrointestinal diseases, and metabolic disorders. One of the company's main divisions is the treatment of obesity and associated comorbidities. Here, the company offers innovative solutions that aim to promote weight loss and minimize the risk of complications. Products in this area include gastric bands, gastric balloons, and other endoscopic procedures that help reduce the size of the stomach and reduce appetite. Another area in which the company operates is the treatment of gastrointestinal diseases. ReShape Lifesciences Inc offers innovative technologies that aim to improve the lives of patients with chronic conditions such as Crohn's disease or ulcerative colitis. One of their key technologies in this area is the Hydro-Sponge capsule, which can help alleviate the symptoms of these diseases. Another important area in which the company operates is the treatment of metabolic disorders. Here, ReShape Lifesciences Inc offers innovative solutions that aim to regulate blood sugar levels and minimize the risk of complications in diabetes. Products in this area include insulin syringes, insulin pumps, and other devices that help optimize therapy and reduce insulin requirements. Overall, ReShape Lifesciences Inc follows a business model based on the development, manufacturing, and marketing of medical devices and technologies that aim to improve people's lives and treat diseases. Through close collaboration with doctors, clinics, and other medical facilities, the company is able to constantly improve its products and meet the needs of patients. To successfully implement its business model, ReShape Lifesciences Inc focuses on strong customer orientation, close collaboration with partners, and continuous innovation. The company strives to offer its customers high-quality products that are state-of-the-art and meet the needs of patients. In summary, ReShape Lifesciences Inc is a leading company in the field of medical innovations that offers a wide range of products and technologies for the treatment of obesity, gastrointestinal diseases, and metabolic disorders. Through strong customer orientation and close collaboration with doctors and clinics, the company is able to offer its customers high-quality and innovative solutions aimed at improving people's lives and treating diseases.

What is the ReShape Lifesciences dividend?

ReShape Lifesciences pays a dividend of 0 USD distributed over payouts per year.

How often does ReShape Lifesciences pay dividends?

The dividend cannot currently be calculated for ReShape Lifesciences or the company does not pay out a dividend.

What is the ReShape Lifesciences ISIN?

The ISIN of ReShape Lifesciences is US7611236032.

What is the ReShape Lifesciences ticker?

The ticker of ReShape Lifesciences is RSLS.

How much dividend does ReShape Lifesciences pay?

Over the past 12 months, ReShape Lifesciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ReShape Lifesciences is expected to pay a dividend of 0 USD.

What is the dividend yield of ReShape Lifesciences?

The current dividend yield of ReShape Lifesciences is .

When does ReShape Lifesciences pay dividends?

ReShape Lifesciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ReShape Lifesciences?

ReShape Lifesciences paid dividends every year for the past 0 years.

What is the dividend of ReShape Lifesciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ReShape Lifesciences located?

ReShape Lifesciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von ReShape Lifesciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ReShape Lifesciences from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did ReShape Lifesciences pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of ReShape Lifesciences in the year 2023?

In the year 2023, ReShape Lifesciences distributed 0 USD as dividends.

In which currency does ReShape Lifesciences pay out the dividend?

The dividends of ReShape Lifesciences are distributed in USD.

All fundamentals about ReShape Lifesciences

Our stock analysis for ReShape Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReShape Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.